Dozens die as dengue surges in Malaysia while vaccine uptake stalls

Dengue infections have spiked sharply in Malaysia, with over 58,000 cases and 55 fatalities reported this year, according to recent data. The surge has raised alarms among health officials, who warn of the growing threat posed by the mosquito-borne virus. Despite the rising number of cases, vaccination rates remain stubbornly low, with fewer citizens opting for the available dengue vaccine. This situation has sparked discussions among medical professionals and public health experts about the barriers preventing widespread immunization. The increase in dengue cases marks a notable rise compared to previous years, with a 56.2 per cent jump observed this year alone. Health authorities have noted that the outbreak has affected multiple regions across the country, though certain urban areas appear to be particularly hard-hit. The high mortality rate underscores the severity of the current wave, prompting calls for increased awareness campaigns and improved access to preventive measures. Dr. Shanmuganathan TV Ganeson, president of the Federation of Private Medical Practitioners’ Associations in Malaysia, highlighted economic factors as a key reason for the low uptake of the dengue vaccine. He stated that the two-dose regimen can range from 420 to 500 ringgit, roughly equivalent to $104 to $124, depending on the healthcare provider. General practitioners offer the vaccine at a lower price than larger hospitals, yet they often lack the resources to promote it effectively. Dr. Ganeson emphasized that the vaccine's affordability remains a challenge, particularly when compared to other commonly administered vaccines such as the influenza shot. The dengue vaccine faces stiff competition from more accessible and affordable options, including the flu vaccine, which costs significantly less, often under 100 ringgit. Dr. Ganeson pointed out that many individuals, especially frequent travelers, prioritize flu protection due to its lower cost and broader accessibility. This preference highlights a gap in public understanding regarding the importance of dengue prevention, despite the risks associated with the disease. Additionally, the vaccine’s eligibility criteria further limit its reach. It is currently approved only for individuals aged between four and 60, excluding pregnant women, breastfeeding mothers, and those with weakened immune systems. These restrictions mean that a large portion of the population remains ineligible, reducing the potential impact of the vaccine in curbing the spread of the virus. Public health officials are now considering strategies to address these challenges. They are exploring ways to improve vaccine education, reduce costs, and expand eligibility criteria to include more vulnerable groups. Efforts are also being made to enhance collaboration between healthcare providers and community leaders to ensure better outreach and information dissemination. As the situation continues to evolve, the focus remains on mitigating the ongoing outbreak through a combination of public health interventions, improved surveillance, and increased vaccination efforts. With the current trajectory, there is a clear need for urgent action to prevent further loss of life and to strengthen Malaysia’s capacity to respond to future outbreaks.